195 related articles for article (PubMed ID: 8452346)
1. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis.
Ashtekar DR; Costa-Perira R; Nagrajan K; Vishvanathan N; Bhatt AD; Rittel W
Antimicrob Agents Chemother; 1993 Feb; 37(2):183-6. PubMed ID: 8452346
[TBL] [Abstract][Full Text] [Related]
2. Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis.
Ashtekar DR; Costa-Periera R; Shrinivasan T; Iyyer R; Vishvanathan N; Rittel W
Diagn Microbiol Infect Dis; 1991; 14(6):465-71. PubMed ID: 1802533
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis.
Upton AM; Cho S; Yang TJ; Kim Y; Wang Y; Lu Y; Wang B; Xu J; Mdluli K; Ma Z; Franzblau SG
Antimicrob Agents Chemother; 2015 Jan; 59(1):136-44. PubMed ID: 25331696
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.
Sasaki H; Haraguchi Y; Itotani M; Kuroda H; Hashizume H; Tomishige T; Kawasaki M; Matsumoto M; Komatsu M; Tsubouchi H
J Med Chem; 2006 Dec; 49(26):7854-60. PubMed ID: 17181168
[TBL] [Abstract][Full Text] [Related]
5. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
Matsumoto M; Hashizume H; Tomishige T; Kawasaki M; Tsubouchi H; Sasaki H; Shimokawa Y; Komatsu M
PLoS Med; 2006 Nov; 3(11):e466. PubMed ID: 17132069
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.
Tyagi S; Nuermberger E; Yoshimatsu T; Williams K; Rosenthal I; Lounis N; Bishai W; Grosset J
Antimicrob Agents Chemother; 2005 Jun; 49(6):2289-93. PubMed ID: 15917523
[TBL] [Abstract][Full Text] [Related]
7. New drugs for tuberculosis.
Grassi C; Peona V
Eur Respir J Suppl; 1995 Sep; 20():714s-718s. PubMed ID: 8590571
[TBL] [Abstract][Full Text] [Related]
8. 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases.
Thompson AM; Blaser A; Palmer BD; Anderson RF; Shinde SS; Launay D; Chatelain E; Maes L; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
Bioorg Med Chem Lett; 2017 Jun; 27(11):2583-2589. PubMed ID: 28462832
[TBL] [Abstract][Full Text] [Related]
9. Mefloquine and its oxazolidine derivative compound are active against drug-resistant Mycobacterium tuberculosis strains and in a murine model of tuberculosis infection.
Rodrigues-Junior VS; Villela AD; Gonçalves RS; Abbadi BL; Trindade RV; López-Gavín A; Tudó G; González-Martín J; Basso LA; de Souza MV; Campos MM; Santos DS
Int J Antimicrob Agents; 2016 Aug; 48(2):203-7. PubMed ID: 27364701
[TBL] [Abstract][Full Text] [Related]
10. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.
Lenaerts AJ; Gruppo V; Marietta KS; Johnson CM; Driscoll DK; Tompkins NM; Rose JD; Reynolds RC; Orme IM
Antimicrob Agents Chemother; 2005 Jun; 49(6):2294-301. PubMed ID: 15917524
[TBL] [Abstract][Full Text] [Related]
11. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents.
Hurdle JG; Lee RB; Budha NR; Carson EI; Qi J; Scherman MS; Cho SH; McNeil MR; Lenaerts AJ; Franzblau SG; Meibohm B; Lee RE
J Antimicrob Chemother; 2008 Nov; 62(5):1037-45. PubMed ID: 18693235
[TBL] [Abstract][Full Text] [Related]
12. Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.
Luo W; Huang Z; Xu D; Yang M; Zhu Y; Shen L; Chen S; Tao X; Bin W; Hu Y; Franzblau SG; Jiang N; Wei Y; Wei X; Ding CZ
Bioorg Med Chem Lett; 2022 Sep; 72():128871. PubMed ID: 35777718
[TBL] [Abstract][Full Text] [Related]
13. Delamanid Kills Dormant Mycobacteria
Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
[TBL] [Abstract][Full Text] [Related]
14. Antituberculosis agents. VI. Activity of a new ciprofloxacin derivative against Mycobacterium avium and some drug-resistant strains of Mycobacterium tuberculosis.
Foroumadi A; Soltani F; Moshafi MH
Boll Chim Farm; 2002; 141(5):394-6. PubMed ID: 12481384
[TBL] [Abstract][Full Text] [Related]
15. The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
Iacobino A; Giannoni F; Pardini M; Piccaro G; Fattorini L
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010861
[TBL] [Abstract][Full Text] [Related]
16. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the ESP culture system II for testing susceptibilities of Mycobacterium tuberculosis isolates to four primary antituberculous drugs.
Bergmann JS; Woods GL
J Clin Microbiol; 1998 Oct; 36(10):2940-3. PubMed ID: 9738047
[TBL] [Abstract][Full Text] [Related]
18. Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages.
Khan A; Sarkar S; Sarkar D
Int J Antimicrob Agents; 2008 Jul; 32(1):40-5. PubMed ID: 18538548
[TBL] [Abstract][Full Text] [Related]
19. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
Kwon YS; Jeong BH; Koh WJ
Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
[TBL] [Abstract][Full Text] [Related]
20. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
